Major Lymphoma Researcher Returning to US

Last week Rita Clementi, 47 years old, mother of three, wrote an open letter to the Italian President, Giorgio Napolitano, saying she was moving to Boston because it had become unbearable for her to continue working in Italy.

Rita Clementi, with a research background that culminated some years ago with the identification of gene expressions in malignant lymphomas, at almost 50, is still a temporary scientist at the University of Pavia.

In her letter to the President of Italy she states that, after so many years of missed opportunities due to an intolerable, nepotistic system she has decided to leave Italy and continue her research in the US where, she says, meritocracy is still the main factor determining the career of people in science.
It is interesting to see other countries struggling with the same “brain drain” that affects so many fields in the US. Italy, with 60 million inhabitants, is the second exporter of brains to the US after India (1 billion people).

She has complained openly about the common practice of forcing researchers to work for a decade or more in universities with only temporary contracts.

"As we strive to defeat cancer, discover new molecules and genes, develop new software, support an ever-changing culture, and identify new ways to teach and learn, remember that achieving these goals is partly due to the work of university researchers with temporary contracts, who have worked for years hoping to finally obtain a job that would give them economic stability and freedom."

A broader look at her concerns about scientific research in Italy can be found here:
http://www.sauvonslarecherche.fr/IMG/pdf/1615b.pdf

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap